Psychological therapies are considered the treatment of choice for functional/dissociative seizures (FDSs). Although most previous studies have focused on seizure persistence or frequency, it has been argued that well-being or health-related quality of life outcomes may actually be more meaningful. This study contributes by summarizing and meta-analyzing non-seizure outcomes to quantify the effectiveness of psychological treatment in this patient group. A pre-registered systematic search identified treatment studies (e.g., cohort studies, controlled trials) in FDSs. Data from these studies were synthesized using multi-variate random-effects meta-analysis. Moderators of treatment effect were examined using treatment characteristics, sample characteristics, and risk of bias. A total of 171 non-seizure outcomes across 32 studies with a pooled sample size of N = 898 yielded a pooled effect-size of d = .51 (moderate effect size). The outcome domain assessed and the type of psychological treatment were significant moderators of reported outcomes. Greater rates of improvement were demonstrated for outcomes assessing general functioning. Behavioral treatments emerged as particularly effective interventions. Psychological interventions are associated with clinical improvements across a broad array of non-seizure outcomes, over and above seizure frequency, in adults with FDSs.

Download full-text PDF

Source
http://dx.doi.org/10.1111/epi.17626DOI Listing

Publication Analysis

Top Keywords

non-seizure outcomes
16
psychological treatment
12
effectiveness psychological
8
functional/dissociative seizures
8
treatment
7
outcomes
7
psychological
5
studies
5
meta-analytic review
4
review effectiveness
4

Similar Publications

Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, cognitive impairment, and distinctive electroencephalographic patterns. Neuromodulation techniques, including vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neurostimulation (RNS), have emerged as important treatment options for patients with LGS who do not respond adequately to antiseizure medications. This review, developed with input from the Pediatric Epilepsy Research Consortium (PERC) LGS Special Interest Group, provides practical guidance for clinicians on the use of these neuromodulation approaches in patients with LGS.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated how metabolic brain network connectivity changes in patients with drug-resistant mesial temporal lobe epilepsy (DR-MTLE) affect surgical outcomes.
  • Patients (87) who underwent surgery were divided into seizure-free (SF) and non-seizure-free (NSF) groups, alongside a control group of healthy individuals (38).
  • Results showed that both patient groups had reduced metabolic connectivity compared to healthy controls, with the NSF group experiencing more significant disruptions, particularly in key brain networks, suggesting potential reasons for poor postoperative seizure control and implications for preoperative assessments.
View Article and Find Full Text PDF

Measuring the Burden of Epilepsy Hospitalizations in CDKL5 Deficiency Disorder.

Pediatr Neurol

November 2024

The Kids Research Institute Australia, The University of Western Australia, Northern Entrance, Western Australia, Australia. Electronic address:

Background: Information on the hospital service use among individuals with CDKL5 Deficiency Disorder, an ultrarare developmental epileptic encephalopathy, is limited, evidence of which could assist with service planning. Therefore, using baseline and longitudinal data on 379 genetically verified individuals in the International CDKL5 Disorder Database, we aimed to investigate rates of seizure-related and other hospitalizations and associated length of stay in this cohort.

Methods: Outcome variables were lifetime count of family-reported hospitalizations and average length of stay both for seizure- (management and/or investigative) and non-seizure-related causes.

View Article and Find Full Text PDF

Dravet syndrome (DS) is a severe genetic developmental and epileptic encephalopathy, primarily caused by SCN1A gene mutations. Historically, treatments like clobazam and valproate have been used without evidence from randomized controlled trials (RCTs). However, the therapeutic landscape of DS has evolved with multiple RCTs demonstrating the efficacy and safety of three antiseizure medications (ASMs): stiripentol, cannabidiol (CBD), and fenfluramine.

View Article and Find Full Text PDF
Article Synopsis
  • Intracranial EEG helps identify networks associated with focal epilepsy, but how these network structures affect post-surgery seizure outcomes is not well understood.
  • The study tested whether better surgical outcomes are linked to removing key brain regions (hubs) involved in seizure activity, measured by a new metric called Resection-Hub Alignment Degree (RHAD).
  • Results indicated that a significant difference in RHAD was found between patients with good and bad surgical results, suggesting that analyzing network hubs offers better insights than traditional methods in predicting post-surgery epilepsy outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!